Page last updated: 2024-09-03

rc 3095 and gemcitabine

rc 3095 has been researched along with gemcitabine in 1 studies

Compound Research Comparison

Studies
(rc 3095)
Trials
(rc 3095)
Recent Studies (post-2010)
(rc 3095)
Studies
(gemcitabine)
Trials
(gemcitabine)
Recent Studies (post-2010) (gemcitabine)
10822612,5233,2086,923

Protein Interaction Comparison

ProteinTaxonomyrc 3095 (IC50)gemcitabine (IC50)
Chain A, DEOXYNUCLEOSIDE KINASEDrosophila melanogaster (fruit fly)0.76
Equilibrative nucleoside transporter 1Homo sapiens (human)0.19

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hong, SK; Yang, KX; Yang, SY; Yin, SH1

Other Studies

1 other study(ies) available for rc 3095 and gemcitabine

ArticleYear
RC-3095, a gastrin-releasing peptide receptor antagonist, synergizes with gemcitabine to inhibit the growth of human pancreatic cancer CFPAC-1 in vitro and in vivo.
    Pancreas, 2014, Volume: 43, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Bombesin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Peptide Fragments; Receptors, Bombesin; Tumor Burden; Xenograft Model Antitumor Assays

2014